Sensitivity analysis In pharmacovigilance studies using the FDA Adverse Event Reporting System (FAERS) database, sensitivity analysis serves to validate the robustness and reliability of drug safety signal detection
Semaglutide deep-dive Semaglutide is sold under three brand names, all manufactured by Novo Nordisk: Ozempic -- weekly injection, FDA-approved for type 2 diabetes (doses 0.25 mg, 0.5 mg, 1 mg, 2 mg) Wegovy -- weekly injection, FDA-approved for chronic weight management in 2021 (doses up to 2.4 mg) [3] Rybelsus -- daily oral tablet, approved for type 2 diabetes For weight loss specifically, Wegovy is the on-label choice

A closer look at how weight loss drug semaglutide improves the cardiovascular health of obese patients without diabetes Weekly treatments of semaglutide can reduce the risk of cardiovascular death, heart attack or stroke among obese patients without diabetes, according to new data presented at the American Heart Associations Scientific Sessions 2023 conference and simultaneously published in The New England Journal of Medicine .[1] Subcutaneous treatments of semaglutide, a GLP-1 receptor agonist originally developed to treat diabetes, are being sold and marketed by Novo Nordisk under the brand name Wegovy
If you have no documented deficiency but feel fatigued on semaglutide, consider that inadequate protein intake, dehydration, or insufficient sleep often explain low energy better than B12 status
Combining GLP-1s with hormone therapy (HT) may improve outcomes, with studies showing up to 35% more weight loss than GLP-1s alone (6)
But not every case of thinning is truly hair loss from semaglutide